# Tocilizumab for Acute Chest Syndrome

> **NCT05640271** · PHASE2 · RECRUITING · sponsor: **University of Chicago** · enrollment: 200 (estimated)

## Conditions studied

- Sickle Cell Disease
- Acute Chest Syndrome

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT05640271
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-10
- **Primary completion:** 2026-07
- **Final completion:** 2027-01
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2026-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05640271

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05640271, "Tocilizumab for Acute Chest Syndrome". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05640271. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*